-
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Carl Fredrik Warfvinge, Johan Gustafsson, Daniel Roth, Jan Tennvall, Johanna Svensson, Peter Bernhardt, Anna Åkesson, Elinore Wieslander, Anna Sundlöv, Katarina Sjögreen Gleisner
Peptide receptor radionuclide therapy presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known. Here, we investigated the relationship between tumor-absorbed dose and
-
Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Jie Zang, Yun Yang, Shaoming Chen, Chao Wang, Shaohao Chen, Shun Hu, Hai Cai, Xiaodong Li, Ning Xu, Xiaoyuan Chen, Jingjing Zhang, Weibing Miao
This study aimed to assess the diagnostic value of [18F]AlF-thretide PET/CT in patients with newly diagnosed prostate cancer (PCa). Methods: In total, 49 patients with biopsy-proven PCa were enrolled in this prospective study. All patients underwent [18F]AlF-thretide PET/CT, and the scoring system of the PRIMARY trial was used for PET image analysis. The dosimetry evaluation of [18F]AlF-thretide was
-
Prognostic Value of [99mTc]Tc-DPD Quantitative SPECT/CT in Patients with Suspected and Confirmed Amyloid Transthyretin–Related Cardiomyopathy and Preserved Left Ventricular Function J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Federico Caobelli, Nasir Gözlügöl, Adam Bakula, Axel Rominger, Robin Schepers, Stefan Stortecky, Lukas Hunziker Munsch, Stephan Dobner, Christoph Gräni
Quantitative 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid ([99mTc]Tc-DPD) SPECT may be used for risk-stratifying patients with amyloid transthyretin–related cardiomyopathy (ATTR-CM). We aimed to analyze the predictive value of quantitative [99mTc]Tc-DPD SPECT/CT in suspected and confirmed ATTR-CM according to different disease stages. Methods: The study enrolled consecutive patients with suspected
-
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Surekha Yadav, Fei Jiang, Sara Kurkowska, Rachelle Saelee, Amanda Morley, Felix Feng, Rahul Aggarwal, Courtney Lawhn-Heath, Carlos Uribe, Thomas A. Hope
Understanding the relationship between lesion-absorbed dose and tumor response in 177Lu-PSMA-617 radiopharmaceutical therapies (RPTs) remains complex. We aimed to investigate whether baseline lesion-absorbed dose can predict lesion-based responses and to explore the connection between lesion-absorbed dose and prostate-specific antigen (PSA) response. Methods: In this retrospective study, we evaluated
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Helena Lanzafame, Ilektra A. Mavroeidi, Kim M. Pabst, Mélanie Desaulniers, Marc Ingenwerth, Nader Hirmas, Lukas Kessler, Michael Nader, Timo Bartel, Stephan Leyser, Francesco Barbato, Martin Schuler, Sebastian Bauer, Jens T. Siveke, Ken Herrmann, Rainer Hamacher, Wolfgang P. Fendler
Fibroblast activation protein-α (FAP) is often highly expressed by sarcoma cells and by sarcoma-associated fibroblasts in the tumor microenvironment. This makes it a promising target for imaging and therapy. The level of FAP expression and the diagnostic value of 68Ga-FAP inhibitor (FAPI) PET for sarcoma subtypes are unknown. We assessed the diagnostic performance and accuracy of 68Ga-FAPI PET in various
-
Determining Hemodynamically Significant Coronary Artery Disease: Patient-Specific Cutoffs in Quantitative Myocardial Blood Flow Using [15O]H2O PET Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Roel Hoek, Pepijn A. van Diemen, Pieter G. Raijmakers, Roel S. Driessen, Yvemarie B.O. Somsen, Ruben W. de Winter, Ruurt A. Jukema, Jos W.R. Twisk, Lourens F.H.J. Robbers, Pim van der Harst, Antti Saraste, Mark Lubberink, Jens Sörensen, Paul Knaapen, Juhani Knuuti, Ibrahim Danad
Currently, cutoffs of quantitative [15O]H2O PET to detect fractional flow reserve (FFR)–defined coronary artery disease (CAD) were derived from a single cohort that included patients without prior CAD. However, prior CAD, sex, and age can influence myocardial blood flow (MBF). Therefore, the present study determined the influence of prior CAD, sex, and age on optimal cutoffs of hyperemic MBF (hMBF)
-
Deep Learning–Enabled Quantification of 99mTc-Pyrophosphate SPECT/CT for Cardiac Amyloidosis J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Robert J.H. Miller, Aakash Shanbhag, Anna M. Michalowska, Paul Kavanagh, Joanna X. Liang, Valerie Builoff, Nowell M. Fine, Damini Dey, Daniel S. Berman, Piotr J. Slomka
Transthyretin cardiac amyloidosis (ATTR CA) is increasingly recognized as a cause of heart failure in older patients, with 99mTc-pyrophosphate imaging frequently used to establish the diagnosis. Visual interpretation of SPECT images is the gold standard for interpretation but is inherently subjective. Manual quantitation of SPECT myocardial 99mTc-pyrophosphate activity is time-consuming and not performed
-
Natural History of Myocardial αvβ3 Integrin Expression After Acute Myocardial Infarction: Correlation with Changes in Myocardial Blood Flow J Nucl. Med. (IF 9.3) Pub Date : 2024-05-09 Matthieu Dietz, Christel H. Kamani, Colin Bousige, Vincent Dunet, Judith Delage, Vladimir Rubimbura, Marie Nicod Lalonde, Giorgio Treglia, Niklaus Schaefer, Wail Nammas, Antti Saraste, Juhani Knuuti, Nathan Mewton, John O. Prior
Visual Abstract
-
Cerebral 18F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment J Nucl. Med. (IF 9.3) Pub Date : 2024-05-02 Yifei Ma, Jiling Zeng, Fadian Ding, Yiwei Xu, Youlong Wang, Guanqing Zhong, Nianqi Liu, Yanqi Wang, Yiming Li, Shuqin Chen, Xiaolong Wei, Pengfei Zhu, Guangmin Jian, Yu Si Niu, Guangzhen Fu, Cantong Liu, Guiqiang Li, Xiaotong Zhou, Ao Zhang, Shangeng Weng
Visual Abstract
-
Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study J Nucl. Med. (IF 9.3) Pub Date : 2024-05-02 Robert Seifert, Tugce Telli, Constantin Lapa, Mélanie Desaulniers, Turkay Hekimsoy, Wolfgang A. Weber, Christian Pfob, Boris Hadaschik, Martin Bögemann, Michael Schäfers, Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Wolfgang P. Fendler
Visual Abstract
-
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG J Nucl. Med. (IF 9.3) Pub Date : 2024-05-02 Brad Kline, Surekha Yadav, Youngho Seo, Robin Cumming Ippisch, Jessa Castillo, Rahul R. Aggarwal, Robin Kate Kelley, Spencer C. Behr, Robert R. Flavell, Courtney Lawhn-Heath, Michelle Melisko, Hope S. Rugo, Victoria Wang, Sue S. Yom, Patrick Ha, Fei Jiang, Thomas A. Hope
Visual Abstract
-
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for 223Ra-Based Radiopharmaceutical Therapies J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Zekun Li, Nadia Benabdallah, Jingqin Luo, Richard L. Wahl, Daniel L.J. Thorek, Abhinav K. Jha
Personalized dose-based treatment planning requires accurate and reproducible noninvasive measurements to ensure safety and effectiveness. Dose estimation using SPECT is possible but challenging for alpha (α)-particle–emitting radiopharmaceutical therapy (α-RPT) because of complex -emission spectra, extremely low counts, and various image-degrading artifacts across a plethora of scanner–collimator
-
Impact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Stefan P. Haider, Tal Zeevi, Kariem Sharaf, Moritz Gross, Amit Mahajan, Benjamin H. Kann, Benjamin L. Judson, Manju L. Prasad, Barbara Burtness, Mariam Aboian, Martin Canis, Christoph A. Reichel, Philipp Baumeister, Seyedmehdi Payabvash
We aimed to investigate the effects of 18F-FDG PET voxel intensity normalization on radiomic features of oropharyngeal squamous cell carcinoma (OPSCC) and machine learning–generated radiomic biomarkers. Methods: We extracted 1,037 18F-FDG PET radiomic features quantifying the shape, intensity, and texture of 430 OPSCC primary tumors. The reproducibility of individual features across 3 intensity-normalized
-
MIRD Pamphlet No. 29: MIRDy90—A 90Y Research Microsphere Dosimetry Tool J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Harry Marquis, Juan C. Ocampo Ramos, Lukas M. Carter, Pat Zanzonico, Wesley E. Bolch, Richard Laforest, Adam L. Kesner
90Y-microsphere radioembolization has become a well-established treatment option for liver malignancies and is one of the first U.S. Food and Drug Administration–approved unsealed radionuclide brachytherapy devices to incorporate dosimetry-based treatment planning. Several different mathematical models are used to calculate the patient-specific prescribed activity of 90Y, namely, body surface area
-
Robust Quantification of Phosphodiesterase-4D in Monkey Brain with PET and 11C-Labeled Radioligands That Avoid Radiometabolite Contamination J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Meijuan Jiang, Shiyu Tang, Madeline D. Jenkins, Adrian C. Lee, Bruny Kenou, Carson Knoer, Jose Montero Santamaria, Shawn Wu, Jeih-San Liow, Sami S. Zoghbi, Paolo Zanotti-Fregonara, Robert B. Innis, Sanjay Telu, Victor W. Pike
Phosphodiesterase-4D (PDE4D) has emerged as a significant target for treating neuropsychiatric disorders, but no PET radioligand currently exists for robustly quantifying human brain PDE4D to assist biomedical research and drug discovery. A prior candidate PDE4D PET radioligand, namely [11C]T1650, failed in humans because of poor time stability of brain PDE4D-specific signal (indexed by total volume
-
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Gihan P. Ruwanpathirana, Robert C. Williams, Colin L. Masters, Christopher C. Rowe, Leigh A. Johnston, Catherine E. Davey
Amyloid-β (Aβ) accumulation in Alzheimer disease (AD) is typically measured using SUV ratio and the centiloid (CL) scale. The low spatial resolution of PET images is known to degrade quantitative metrics because of the partial-volume effect. This article examines the impact of spatial resolution, as determined by the reconstruction configuration, on the Aβ PET quantitation in both cross-sectional and
-
Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Xiuli Zhang, Gyu Seong Heo, Alexandria Li, Divangana Lahad, Lisa Detering, Joan Tao, Xuefeng Gao, Xiaohui Zhang, Hannah Luehmann, Deborah Sultan, Lanlan Lou, Rajiu Venkatesan, Ran Li, Jie Zheng, Junedh Amrute, Chieh-Yu Lin, Benjamin J. Kopecky, Robert J. Gropler, Andrea Bredemeyer, Kory Lavine, Yongjian Liu
Tissue-resident macrophages are complementary to proinflammatory macrophages to promote the progression of atherosclerosis. The noninvasive detection of their presence and dynamic variation will be important to the understanding of their role in the pathogenesis of atherosclerosis. The goal of this study was to develop a targeted PET radiotracer for imaging CD163-positive (CD163+) macrophages in multiple
-
Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Attila Feher, Bryan Bednarski, Robert J. Miller, Aakash Shanbhag, Mark Lemley, Leonidas Miras, Albert J. Sinusas, Edward J. Miller, Piotr J. Slomka
Heart failure (HF) is a leading cause of morbidity and mortality in the United States and worldwide, with a high associated economic burden. This study aimed to assess whether artificial intelligence models incorporating clinical, stress test, and imaging parameters could predict hospitalization for acute HF exacerbation in patients undergoing SPECT/CT myocardial perfusion imaging. Methods: The HF
-
Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Frédéric Massière, Norbert Wiedemann, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Matthias Paschke, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Franck Brichory, Antoine Attinger
The membrane protein carbonic anhydrase IX (CAIX) is highly expressed in many hypoxic or von Hippel-Lindau tumor suppressor–mutated tumor types. Its restricted expression in healthy tissues makes CAIX an attractive diagnostic and therapeutic target. DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, allowing radionuclide chelation for theranostic purposes. Here, we report CAIX expression
-
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [177Lu]Lu-DOTATATE J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Johan Blakkisrud, Avery B. Peterson, Scott J. Wildermann, Griffen Kingkiner, Ka Kit Wong, Chang Wang, Kirk A. Frey, Caroline Stokke, Yuni K. Dewaraja
Hematologic toxicity, although often transient, is the most common limiting adverse effect during somatostatin peptide receptor radionuclide therapy. This study investigated the association between Monte Carlo–derived absorbed dose to the red marrow (RM) and hematologic toxicity in patients being treated for their neuroendocrine tumors. Methods: Twenty patients each receiving 4 treatment cycles of
-
Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Ebrahim S. Delpassand, Soheil M. Yazdi, Shashank Ghantoji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang, Jeetvan Patel
Advanced neuroendocrine tumors (NETs) are associated with a poor prognosis. A regimen of 4 cycles of 177Lu-DOTATATE has been shown to improve both progression-free survival (PFS) and overall survival (OS) in patients with advanced NETs. To the best of our knowledge, this is the first study in the United States to evaluate the effectiveness and safety of additional cycles of 177Lu-DOTATATE therapy in
-
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Michael S. Hofman, Ben Tran, Darren R. Feldman, Anna Pokorska-Bocci, Solen Pichereau, Jonathan Wessen, Mohammad B. Haskali, Richard B. Sparks, Olena Vlasyuk, Ivana Galetic
[68Ga]Ga-DPI-4452, a first-in-class carbonic anhydrase IX–binding radiolabeled peptide, is the imaging agent of a theranostic pair with [177Lu]Lu-DPI-4452, developed for selecting and treating patients with carbonic anhydrase IX–expressing tumors. Here, [68Ga]Ga-DPI-4452 imaging characteristics, dosimetry, pharmacokinetics, and safety were assessed in 3 patients with clear cell renal cell carcinoma
-
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim, Rachelle K. Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, Thomas A. Hope
We report our initial real-world experience with 177Lu-PSMA-617 radioligand therapy. Methods: We performed a retrospective review of patients treated with 177Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated. Results: Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of
-
Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Ning Liu, Xiujie Yang, Chao Gao, Jianze Wang, Yuwen Zeng, Linyu Zhang, Qi Yin, Ting Zhang, Haoyi Zhou, Kui Li, Jinhong Du, Shixin Zhou, Xuyang Zhao, Hua Zhu, Zhi Yang, Zhaofei Liu
Immune checkpoint blockade (ICB) has achieved groundbreaking results in clinical cancer therapy; however, only a subset of patients experience durable benefits. The aim of this study was to explore strategies for predicting tumor responses to optimize the intervention approach using ICB therapy. Methods: We used a bilateral mouse model for proteomics analysis to identify new imaging biomarkers for
-
18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Samuel L. Cytryn, Neeta Pandit-Taskar, Melissa A. Lumish, Steven B. Maron, Ping Gu, Geoffrey Y. Ku, Joanne F. Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, Lara Feder, Steven Philemond, Serge K. Lyashchenko, Jason S. Lewis, Viktoriya Paroder, Amitabh Srivastava, Laura H. Tang, Heiko Schoder, Yelena Y. Janjigian
Anti–programmed death 1 (PD-1) inhibitors are the standard of care for advanced gastroesophageal cancer. Although recommendations and approval by regulatory agencies are often based on programmed death ligand 1 (PD-L1) expression, pathologic assessments of PD-L1 status have several limitations. Single-site biopsies do not adequately capture disease heterogeneity within individual tumor lesions or among
-
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Yiran Wang, Yasser G. Abdelhafez, Benjamin A. Spencer, Rashmi Verma, Mamta Parikh, Nicholas Stollenwerk, Lorenzo Nardo, Terry Jones, Ramsey D. Badawi, Simon R. Cherry, Guobao Wang
The lungs are supplied by both the pulmonary arteries carrying deoxygenated blood originating from the right ventricle and the bronchial arteries carrying oxygenated blood downstream from the left ventricle. However, this effect of dual blood supply has never been investigated using PET, partially because the temporal resolution of conventional dynamic PET scans is limited. The advent of PET scanners
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escriva-de-Romani, Lourdes Calvo Martínez, Nuria Ribelles, María Fernandez-Abad, Cinta Albacar, Marco Colleoni, Laia Garrigos, Manuel Atienza de Frutos, Florence Dalenc, Aleix Prat, Frederik Marmé, Peter Schmid, Khaldoun Kerrou, Sofia Braga, Petra Gener, Miguel Sampayo-Cordero
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)–positive, invasive, operable breast cancer with at least 1 breast lesion evaluable by [18F]FDG PET/CT. [18F]FDG PET/CT responders were defined as patients with an SUVmax reduction (SUVmax) of at least 40% in all of their target lesions
-
Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Renske Altena, Siri af Burén, August Blomgren, Emelie Karlsson, Antonios Tzortzakakis, Nikolai Brun, Mohammad M. Moein, Emma Jussing, Fredrik Y. Frejd, Jonas Bergh, Thuy A. Tran, Johan Hartman, Rimma Axelsson
Patients with HER2-low metastatic breast cancer (mBC), defined as an immunohistochemistry (IHC) score of 1+ or 2+ without HER2 gene amplification, may benefit from HER2 antibody–drug conjugates. Identifying suitable candidates is a clinical challenge because of spatial and temporal heterogeneity in HER2 expression and discrepancies in pathologic reporting. We aimed to investigate the feasibility and
-
Cancer Risk in Graves Disease with Radioactive 131I Treatment: A Nationwide Cohort Study J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Radioactive 131I (RAI) therapy has potential effects for the treatment of Graves disease (GD). However, whether RAI therapy for GD increases cancer risk remains controversial in medicine and public health. We aimed to investigate whether the risk of cancer increases in patients with GD receiving RAI therapy compared with those who did not. Methods: We used the Korean National Health Insurance Service’s
-
[18F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Ilanah J. Pruis, Frederik A. Verburg, Rutger K. Balvers, Anita A. Harteveld, Richard A. Feelders, Meike W. Vernooij, Marion Smits, Sebastian J.C.M.M. Neggers, Sophie E.M. Veldhuijzen van Zanten
Small functional pituitary tumors can cause severely disabling symptoms and early death. The gold standard diagnostic approach includes laboratory tests and MRI, with or without inferior petrosal sinus sampling (IPSS). In up to 40% of patients, however, the source of excess hormone production remains unidentified or uncertain. This excludes patients from surgical, Gamma Knife, and CyberKnife therapy
-
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm? J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 Paul Viscuse, Michael Devitt, Robert Dreicer
Most men with newly appreciated metastatic prostate cancer are optimally treated with a backbone consisting of androgen receptor–directed therapy with or without taxane chemotherapy. Despite improvements in disease outcomes, prostate cancer remains an extremely heterogeneous disease with variable mechanisms of therapeutic resistance. As a result, it remains a leading cause of cancer-related death in
-
Quantitative Brain Amyloid PET J Nucl. Med. (IF 9.3) Pub Date : 2024-05-01 William J. Jagust, Venkata S. Mattay, Daniel M. Krainak, Sue-Jane Wang, Lora D. Weidner, A. Alex Hofling, Hayoung Koo, Pamela Hsieh, Phillip H. Kuo, Gill Farrar, Libero Marzella
Since the development of amyloid tracers for PET imaging, there has been interest in quantifying amyloid burden in the brains of patients with Alzheimer disease. Quantitative amyloid PET imaging is poised to become a valuable approach in disease staging, theranostics, monitoring, and as an outcome measure for interventional studies. Yet, there are significant challenges and hurdles to overcome before
-
Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas J Nucl. Med. (IF 9.3) Pub Date : 2024-04-25 Wenhui Zhou, Sumit Halder, Sanna Herwald, Michael Ghijsen, Gowhar Shafi, Mohan Uttarwar, Eric Rosen, Benjamin Franc, Sirish Kishore
Visual Abstract
-
MRI and 18F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis J Nucl. Med. (IF 9.3) Pub Date : 2024-04-25 Jurij Rosen, Jan-Michael Werner, Garry S. Ceccon, Elena K. Rosen, Michael M. Wollring, Isabelle Stetter, Philipp Lohmann, Felix M. Mottaghy, Gereon R. Fink, Karl-Josef Langen, Norbert Galldiks
Visual Abstract
-
Evaluation of Neurodegenerative Disorders with Amyloid-β, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls J Nucl. Med. (IF 9.3) Pub Date : 2024-04-25 Brian J. Burkett, Derek R. Johnson, Val J. Lowe
Antiamyloid therapies for Alzheimer disease recently entered clinical practice, making imaging biomarkers for Alzheimer disease even more relevant to guiding patient management. Amyloid and tau PET are valuable tools that can provide objective evidence of Alzheimer pathophysiology in living patients and will increasingly be used to complement 18F-FDG PET in the diagnostic evaluation of cognitive impairment
-
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-25 Heying Duan, Hong Song, Guido A. Davidzon, Farshad Moradi, Tie Liang, Andreas Loening, Shreyas Vasanawala, Andrei Iagaru
Visual Abstract
-
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial) J Nucl. Med. (IF 9.3) Pub Date : 2024-04-25 John Nikitas, Ethan Lam, Kiara Adame Booker, Wolfgang P. Fendler, Matthias Eiber, Boris Hadaschik, Ken Herrmann, Nader Hirmas, Helena Lanzafame, Martin Stuschke, Johannes Czernin, Michael L. Steinberg, Nicholas G. Nickols, Amar U. Kishan, Jeremie Calais
Visual Abstract
-
Dose Reduction in Pediatric Oncology Patients with Delayed Total-Body [18F]FDG PET/CT J Nucl. Med. (IF 9.3) Pub Date : 2024-04-25 Clemens Mingels, Benjamin A. Spencer, Hande Nalbant, Negar Omidvari, Mehrad Rokni, Axel Rominger, Fatma Sen, Simon R. Cherry, Ramsey D. Badawi, Yasser G. Abdelhafez, Lorenzo Nardo
Visual Abstract
-
Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Alexandros Moraitis, Walter Jentzen, Pedro Fragoso Costa, David Kersting, Stephan Himmen, Marta Coelho, Marian Meckel, Cees J.A. van Echteld, Wolfgang P. Fendler, Ken Herrmann, Miriam Sraieb
Visual Abstract
-
A Deep-Learning–Based Partial-Volume Correction Method for Quantitative 177Lu SPECT/CT Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Julian Leube, Johan Gustafsson, Michael Lassmann, Maikol Salas-Ramirez, Johannes Tran-Gia
Visual Abstract
-
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of 18F-FDG PET/CT and Conventional CT Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Rebecca Moser, Sophie Pfeiffer, Lisena Cala, Evelyn Klein, Marion Kiechle, Sophie T. Behzadi, Eva Fallenberg, Stephanie E. Combs, Wolfgang Weber, Kai J. Borm
Visual Abstract
-
RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Andrei Gafita, Loic Djaileb, Isabel Rauscher, Wolfgang P. Fendler, Boris Hadaschik, Steven P. Rowe, Ken Herrmann, Lilja B. Solnes, Jeremie Calais, Matthew B. Rettig, Manuel Weber, Andrea Farolfi, Matthias R. Benz, Matthias Eiber
Visual Abstract
-
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Marinus J. Hagens, Pim J. van Leeuwen, Maurits Wondergem, Thierry N. Boellaard, Francesco Sanguedolce, Daniela E. Oprea-Lager, Axel Bex, André N. Vis, Henk G. van der Poel, Laura S. Mertens, in collaboration with the EAU Section of Urological Imaging
Visual Abstract
-
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
Visual Abstract
-
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Mina Swiha, Nathan Papa, Zahra Sabahi, Narjess Ayati, Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, Sherrington Li, Shikha Agrawal, Maria Ayers, Adam Hickey, Shikha Sharma, Andrew Nguyen, Louise Emmett
Visual Abstract
-
Mapping 18F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Qi Wu, Fengyun Gu, Liam D. O’Suilleabhain, Hasan Sari, Song Xue, Kuangyu Shi, Axel Rominger, Finbarr O’Sullivan
Visual Abstract
-
PET Quantification of [18F]VAT in Human Brain and Its Test–Retest Reproducibility and Age Dependence J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 John L. O’Donnell, Anil Kumar Soda, Hao Jiang, Scott A. Norris, Baijayanta Maiti, Morvarid Karimi, Meghan C. Campbell, Stephen M. Moerlein, Zhude Tu, Joel S. Perlmutter
Visual Abstract
-
68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Changsong Qi, Rui Guo, Yan Chen, Chenzhen Li, Chang Liu, Miao Zhang, Cheng Zhang, Xiaotian Zhang, Xingguo Hou, Bo Chen, Bing Jia, Zhi Yang, Lin Shen, Hua Zhu
Visual Abstract
-
Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG–Negative Pulmonary Lesions J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Manuel Röhrich, Johanna Daum, Ewgenija Gutjahr, Anna-Maria Spektor, Frederik M. Glatting, Yasemin Aylin Sahin, Hans Georg Buchholz, Jorge Hoppner, Cathrin Schroeter, Eleni Mavriopoulou, Kai Schlamp, Matthias Grott, Florian Eichhorn, Claus Peter Heußel, Hans Ulrich Kauczor, Michael Kreuter, Frederik Giesel, Mathias Schreckenberger, Hauke Winter, Uwe Haberkorn
Visual Abstract
-
Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620 J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Gérard N. Bischof, Matthias Brendel, Henryk Barthel, Hendrik Theis, Michael Barbe, Peter Bartenstein, Joseph Claasen, Adrian Danek, Günter Höglinger, Johannes Levin, Ken Marek, Bernd Neumaier, Carla Palleis, Marianne Patt, Michael Rullmann, Dorothee Saur, Matthias L. Schroeter, John Seibyl, Mengmeng Song, Andrew Stephens, Osama Sabri, Alexander Drzezga, Thilo van Eimeren, for the German Imaging Initiative
Visual Abstract
-
Detecting High-Dose Methotrexate–Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [18F]FDG PET/MRI: A Pilot Study J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Lucia Baratto, Shashi B. Singh, Sharon E. Williams, Sheri L. Spunt, Jarrett Rosenberg, Lisa Adams, Vidyani Suryadevara, Michael Iv, Heike Daldrup-Link
Visual Abstract
-
Impact of PET Reconstruction on Amyloid-{beta} Quantitation in Cross-Sectional and Longitudinal Analyses J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Ruwanpathirana, G. P., Williams, R. C., Masters, C. L., Rowe, C. C., Johnston, L. A., Davey, C. E.
Visual Abstract
-
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Martin Schuler, Jörg Hense, Kaid Darwiche, Sebastian Michels, Hubertus Hautzel, Carsten Kobe, Smiths Lueong, Martin Metzenmacher, Thomas Herold, Gregor Zaun, Katharina Laue, Alexander Drzezga, Dirk Theegarten, Felix Nensa, Jürgen Wolf, Ken Herrmann, Marcel Wiesweg
Visual Abstract
-
The Accomplishments and Legacy of Saul Hertz, MD J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Bennett S. Greenspan, Michael S. Hofman, John Buscombe
The early history of the use of radioactive iodine (RAI) is complicated and interesting, and also difficult to discover, especially since several histories have presented inaccurate content. This article is a comprehensive review of the accomplishments of Saul Hertz. Extensive use of primary-source verification has clarified several issues, including the question of whether Hertz alone conceived and
-
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Guiyu Li, Wenhui Ma, Xiang Li, Weidong Yang, Zhiyong Quan, Taoqi Ma, Junling Wang, Yunya Wang, Fei Kang, Jing Wang
The uMI Panorama is a novel PET/CT system using silicon photomultiplier and application-specific integrated circuit technologies and providing exceptional spatial and time-of-flight (TOF) resolutions. The objective of this study was to assess the physical performance of the uMI Panorama in accordance with the National Electrical Manufacturers Association (NEMA) NU 2-2018 standard. Methods: Spatial
-
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Leung, K. H., Rowe, S. P., Sadaghiani, M. S., Leal, J. P., Mena, E., Choyke, P. L., Du, Y., Pomper, M. G.
Automatic detection and characterization of cancer are important clinical needs to optimize early treatment. We developed a deep, semisupervised transfer learning approach for fully automated, whole-body tumor segmentation and prognosis on PET/CT. Methods: This retrospective study consisted of 611 18F-FDG PET/CT scans of patients with lung cancer, melanoma, lymphoma, head and neck cancer, and breast
-
Promising Candidate Prognostic Biomarkers in [18F]FDG PET Images: Evaluation in Independent Cohorts of Non–Small Cell Lung Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Nicolas Captier, Christophe Nioche, Vesna Cuplov, Erwin Woff, Nadia Hegarat, Alain Livartowski, Nicolas Girard, Irène Buvat, Fanny Orlhac
The normalized distances from the hot spot of radiotracer uptake (SUVmax) to the tumor centroid (NHOC) and to the tumor perimeter (NHOP) have recently been suggested as novel PET features reflecting tumor aggressiveness. These biomarkers characterizing the shift of SUVmax toward the lesion edge during tumor progression have been shown to be prognostic factors in breast and non–small cell lung cancer
-
PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, Ulrike Schick
In lung cancer patients, radiotherapy is associated with a increased risk of local relapse (LR) when compared with surgery but with a preferable toxicity profile. The KEAP1/NFE2L2 mutational status (MutKEAP1/NFE2L2) is significantly correlated with LR in patients treated with radiotherapy but is rarely available. Prediction of MutKEAP1/NFE2L2 with noninvasive modalities could help to further personalize
-
Clinical Evaluation of Deep Learning for Tumor Delineation on 18F-FDG PET/CT of Head and Neck Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 David G. Kovacs, Claes N. Ladefoged, Kim F. Andersen, Jane M. Brittain, Charlotte B. Christensen, Danijela Dejanovic, Naja L. Hansen, Annika Loft, Jørgen H. Petersen, Michala Reichkendler, Flemming L. Andersen, Barbara M. Fischer
Artificial intelligence (AI) may decrease 18F-FDG PET/CT–based gross tumor volume (GTV) delineation variability and automate tumor-volume–derived image biomarker extraction. Hence, we aimed to identify and evaluate promising state-of-the-art deep learning methods for head and neck cancer (HNC) PET GTV delineation. Methods: We trained and evaluated deep learning methods using retrospectively included
-
[18F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Joanna C. Porter, Balaji Ganeshan, Thida Win, Francesco Fraioli, Saif Khan, Manuel Rodriguez-Justo, Raymond Endozo, Robert I. Shortman, Luke R. Hoy, Toby M. Maher, Ashley M. Groves
The use of [18F]FDG PET/CT as a biomarker in diffuse lung diseases is increasingly recognized. We investigated the correlation between [18F]FDG uptake with histologic markers on lung biopsy of patients with fibrotic interstitial lung disease (fILD). Methods: We recruited 18 patients with fILD awaiting lung biopsy for [18F]FDG PET/CT. We derived a target-to-background ratio (TBR) of maximum pulmonary